| |
Presentation |
Media |
Date |
|
AlzeCure at Nordic American Healthcare Conference, December 6-7, 2023
|
|
|
December 6, 2023
|
|
AlzeCure at Redeye Life Science Day 2023 on November 23, 2023
|
|
|
November 23, 2023
|
|
NeuroRestore ACD856, a Trk-PAM in clinical development for Alzheimer’s disease shows neuroprotective and neurorestorative effects_CTAD 2023
|
|
|
October 25, 2023
|
|
Clinical results from phase II study with ACD440 in patients with peripheral neuropathic pain. Scientific presentation at the Svenskt Smärtforum conference Oct 12- 13, 2023.
|
|
|
October 12, 2023
|
|
AlzeCure at Redeye Neurology Theme Event CEO Martin Jönsson presented and answered questions about the latest developments and the company’s plans going forward.
|
|
|
October 11, 2023
|
|
Article from Life Science Sweden – DUAL ACTION AGAINST ALZHEIMER’S IN ALZSTATIN
|
|
|
October 2, 2023
|
|
AlzeCure ACD440 TRPV1 antagonist Ph 2 data, EFIC 2023
|
|
|
September 20, 2023
|
|
AlzeCure Pharma present at Finwire – CSO Johan Sandin
|
|
|
September 5, 2023
|
|
AlzeCure Pharma present at Finwire
|
|
|
September 5, 2023
|
|
AlzeCure Pharma present at Finwire – CMO Märta Segerdahl
|
|
|
September 5, 2023
|
|
AlzeCure Pharma’s CEO Martin Jönsson – Infocus interview at Redeye Growth Day on June 1th , 2023
|
|
|
June 1 , 2023
|
|
AlzeCure presents at Redeye Growth Day on June 1st , 2023
|
|
|
June 1, 2023
|
|
AlzeCure Pharma – Capital Market Day May 17th, 2023
|
|
|
May 17, 2023
|
|
Alzheimer’s disease; Challenges & Opportunities with Professor Bengt Winblad Karolinska Institutet
|
|
|
May 17, 2023
|
|
Presentation of the development of AlzeCure’s Alzheimer project Alzstatin and NeuroRestore
|
|
|
May 17, 2023
|
|
Alzstatin – A preventive treatment against Alzheimer’s – Background & Evolution with Johan Sandin
|
|
|
May 17, 2023
|
|
NeuroRestore: Background & data supporting disease modifying effects with Pontus Forsell
|
|
|
May 17, 2023
|
|
Interview at Finwire with CEO Martin Jönsson
|
|
|
May 9, 2023
|
|
CEO Martin Jönsson at Redeye (Swedish)
|
|
|
April 12, 2023
|
|
In vitro and in vivo profile of AC-0027875 (Alzstatin ACD680), a novel gamma-secretase modulator for the prevention and treatment of Alzheimer’s disease; AD/PD 2023, March 28 – April 1, 2023
|
|
|
March 28, 2023
|
|
Effects on neuroprotection and neuro plasticity by the clinical compound ACD856, a novel positive modulator of Trk-receptors from the NeuroRestore® platform; AD/PD 2023, March 28 – April 1, 2023
|
|
|
March 28, 2023
|
|
CEO Martin Jönsson participated in Redeye Alzheimer Seminar (Swedish)
|
|
|
March 15, 2023
|
|
Sitdown at Finwire with CEO Martin Jönsson
|
|
|
March, 2023
|
|
Watch the interview at Redeye with CEO Martin Jönsson and Märta Segerdahl MD, PhD. Last patient included in AlzeCure’s Phase II clinical trial in peripheral neuropathic pain with the non-opioid ACD440. (Swedish)
|
|
|
January 31, 2023
|
|
CEO Martin Jönsson’s interview with Redeye, the outcome of the issue and milestones in 2023, 9 January (Swedish)
|
|
|
January 9, 2023
|
